2010 American Heart Association

S906 Circulation November 2, 2010
396. Yuan TH, Kerns WPI, Tomaszewski CA, Ford MD, Kline JA. Insulinglucose
as adjunctive therapy for severe calcium channel antagonist
poisoning. J Toxicol Clin Toxicol. 1999;37:463–474.
397. Kerns W, II, Kline J, Ford MD. Beta-blocker and calcium channel
blocker toxicity. Emerg Med Clin North Am. 1994;12:365–390.
398. Lewis M, Kallenbach J, Germond C, Zaltzman M, Muller F, Steyn J,
Zwi S. Survival following massive overdose of adrenergic blocking
agents (acebutolol and labetalol). Eur Heart J. 1983;4:328–332.
399. Cruickshank JM, Neil-Dwyer G, Cameron MM, McAinsh J. beta-Adrenoreceptor-blocking
agents and the blood-brain barrier. Clin Sci. 1980;
59(suppl 6):453s–455s.
400. Weinstein RS. Recognition and management of poisoning with betaadrenergic
blocking agents. Ann Emerg Med. 1984;13:1123–1131.
401. Avery GJd, Spotnitz HM, Rose EA, Malm JR, Hoffman BF. Pharmacologic
antagonism of beta-adrenergic blockade in dogs, I: hemodynamic
effects of isoproterenol, dopamine, and epinephrine in acute propranolol
administration. J Thorac Cardiovasc Surg. 1979;77:267–276.
402. Zaritsky AL, Horowitz M, Chernow B. Glucagon antagonism of calcium
channel blocker-induced myocardial dysfunction. Crit Care Med. 1988;
16:246–251.
403. Mofenson HC, Caraccio TR, Laudano J. Glucagon for propranolol
overdose. JAMA. 1986;255:2025–2026.
404. Love JN, Hanfling D, Howell JM. Hemodynamic effects of calcium
chloride in a canine model of acute propranolol intoxication. Ann Emerg
Med. 1996;28:1–6.
405. Haddad LM. Resuscitation after nifedipine overdose exclusively with
intravenous calcium chloride. Am J Emerg Med. 1996;14:602–603.
406. McGuire W, Fowlie PW. Naloxone for narcotic exposed newborn
infants: systematic review. Arch Dis Child Fetal Neonatal Ed. 2003;88:
F308–F311.
407. Chernick V, Manfreda J, De Booy V, Davi M, Rigatto H, Seshia M.
Clinical trial of naloxone in birth asphyxia. J Pediatr. 1988;113:
519–525.
408. Fischer CG, Cook DR. The respiratory and narcotic antagonistic effects
of naloxone in infants. Anesth Analg. 1974;53:849–852.
409. Kattwinkel J, Niermeyer S, Nadkarni V, Tibballs J, Phillips B, Zideman
D, Van Reempts P, Osmond M. An advisory statement from the
Pediatric Working Group of the International Liaison Committee on
Resuscitation. Middle East J Anesthesiol. 2001;16:315–351.
410. Am Academy of Pediatrics Committee on Drugs: Naloxone dosage and
route of administration for infants and children: addendum to emergency
drug doses for infants and children. Pediatrics. 1990;86:484–485.
411. Mills CA, Flacke JW, Flacke WE, Bloor BC, Liu MD. Narcotic reversal
in hypercapnic dogs: comparison of naloxone and nalbuphine. Can J
Anaesth. 1990;37:238–244.
412. Tobias JD, Lynch A, Garrett J. Alterations of end-tidal carbon dioxide
during the intrahospital transport of children. Pediatr Emerg Care.
1996;12:249–251.
413. Singh S, Allen WD, Jr., Venkataraman ST, Bhende MS. Utility of a
novel quantitative handheld microstream capnometer during transport of
critically ill children. Am J Emerg Med. 2006;24:302–307.
414. Hildebrand CA, Hartmann AG, Arcinue EL, Gomez RJ, Bing
RJ. Cardiac performance in pediatric near-drowning. Crit Care Med.
1988;16:331–335.
415. Checchia PA, Sehra R, Moynihan J, Daher N, Tang W, Weil MH.
Myocardial injury in children following resuscitation after cardiac arrest.
Resuscitation. 2003;57:131–137.
416. Laurent I, Monchi M, Chiche JD, Joly LM, Spaulding C, Bourgeois B,
Cariou A, Rozenberg A, Carli P, Weber S, Dhainaut JF. Reversible
myocardial dysfunction in survivors of out-of-hospital cardiac arrest.
J Am Coll Cardiol. 2002;40:2110–2116.
417. Mayr V, Luckner G, Jochberger S, Wenzel V, Ulmer H, Pajk W,
Knotzer H, Friesenecker B, Lindner K, Hasibeder W, Dunser M.
Arginine vasopressin in advanced cardiovascular failure during the postresuscitation
phase after cardiac arrest. Resuscitation. 2007;72:35–44.
418. Kern KB, Hilwig RW, Berg RA, Rhee KH, Sanders AB, Otto CW, Ewy
GA. Postresuscitation left ventricular systolic and diastolic dysfunction:
treatment with dobutamine. Circulation. 1997;95:2610–2613.
419. Meyer RJ, Kern KB, Berg RA, Hilwig RW, Ewy GA. Post-resuscitation
right ventricular dysfunction: delineation and treatment with dobutamine.
Resuscitation. 2002;55:187–191.
420. Ceneviva G, Paschall JA, Maffei F, Carcillo JA. Hemodynamic support
in fluid-refractory pediatric septic shock. Pediatrics. 1998;102:e19.
421. Huang L, Weil MH, Sun S, Cammarata G, Cao L, Tang W. Levosimendan
improves postresuscitation outcomes in a rat model of CPR.
J Lab Clin Med. 2005;146:256–261.
422. Huang L, Weil MH, Tang W, Sun S, Wang J. Comparison between
dobutamine and levosimendan for management of postresuscitation
myocardial dysfunction. Crit Care Med. 2005;33:487–491.
423. Studer W, Wu X, Siegemund M, Marsch S, Seeberger M, Filipovic M.
Influence of dobutamine on the variables of systemic haemodynamics,
metabolism, and intestinal perfusion after cardiopulmonary resuscitation
in the rat. Resuscitation. 2005;64:227–232.
424. Vasquez A, Kern KB, Hilwig RW, Heidenreich J, Berg RA, Ewy GA.
Optimal dosing of dobutamine for treating post-resuscitation left ventricular
dysfunction. Resuscitation. 2004;61:199–207.
425. Alvarez J, Bouzada M, Fernandez AL, Caruezo V, Taboada M,
Rodriguez J, Ginesta V, Rubio J, Garcia-Bengoechea JB, Gonzalez-
Juanatey JR. [Hemodynamic effects of levosimendan compared with
dobutamine in patients with low cardiac output after cardiac surgery].
Rev Esp Cardiol. 2006;59:338–345.
426. Jorgensen K, Bech-Hanssen O, Houltz E, Ricksten SE. Effects of levosimendan
on left ventricular relaxation and early filling at maintained
preload and afterload conditions after aortic valve replacement for aortic
stenosis. Circulation. 2008;117:1075–1081.
427. Lobato EB, Willert JL, Looke TD, Thomas J, Urdaneta F. Effects of
milrinone versus epinephrine on left ventricular relaxation after cardiopulmonary
bypass following myocardial revascularization: assessment
by color m-mode and tissue Doppler. J Cardiothorac Vasc Anesth.
2005;19:334–339.
428. Nijhawan N, Nicolosi AC, Montgomery MW, Aggarwal A, Pagel PS,
Warltier DC. Levosimendan enhances cardiac performance after cardiopulmonary
bypass: a prospective, randomized placebo-controlled trial.
J Cardiovasc Pharmacol. 1999;34:219–228.
429. Levy B, Bollaert PE, Charpentier C, Nace L, Audibert G, Bauer P, Nabet
P, Larcan A. Comparison of norepinephrine and dobutamine to epinephrine
for hemodynamics, lactate metabolism, and gastric tonometric variables
in septic shock: a prospective, randomized study. Intensive Care
Med. 1997;23:282–287.
430. Zaritsky A, Chernow B. Use of catecholamines in pediatrics. J Pediatr.
1984;105:341–350.
431. Steinberg C, Notterman DA. Pharmacokinetics of cardiovascular drugs
in children. Inotropes and vasopressors. Clin Pharmacokinet. 1994;27:
345–367.
432. Berg RA, Padbury JF. Sulfoconjugation and renal excretion contribute
to the interpatient variation of exogenous catecholamine clearance in
critically ill children. Crit Care Med. 1997;25:1247–1251.
433. Fisher DG, Schwartz PH, Davis AL. Pharmacokinetics of exogenous
epinephrine in critically ill children. Crit Care Med. 1993;21:111–117.
434. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C,
Brasseur A, Defrance P, Gottignies P, Vincent JL. Comparison of
dopamine and norepinephrine in the treatment of shock. N Engl J Med.
2010;362:779–789.
435. Ushay HM, Notterman DA. Pharmacology of pediatric resuscitation.
Pediatr Clin North Am. 1997;44:207–233.
436. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose
dopamine in patients with early renal dysfunction: a placebo-controlled
randomised trial. Australian and New Zealand Intensive Care Society
(ANZICS) Clinical Trials Group. Lancet. 2000;356:2139–2143.
437. Zacharias M, Conlon NP, Herbison GP, Sivalingam P, Walker RJ,
Hovhannisyan K. Interventions for protecting renal function in the
perioperative period. Cochrane Database Syst Rev. 2008;:CD003590.
438. Li J, Zhang G, Holtby H, Humpl T, Caldarone CA, Van Arsdell GS,
Redington AN. Adverse effects of dopamine on systemic hemodynamic
status and oxygen transport in neonates after the Norwood procedure.
J Am Coll Cardiol. 2006;48:1859–1864.
439. Ruffolo RR, Jr., Spradlin TA, Pollock GD, Waddell JE, Murphy PJ.
Alpha and beta adrenergic effects of the stereoisomers of dobutamine.
J Pharmacol Exp Ther. 1981;219:447–452.
440. Habib DM, Padbury JF, Anas NG, Perkin RM, Minegar C. Dobutamine
pharmacokinetics and pharmacodynamics in pediatric intensive care
patients. Crit Care Med. 1992;20:601–608.
441. Martinez AM, Padbury JF, Thio S. Dobutamine pharmacokinetics and
cardiovascular responses in critically ill neonates. Pediatrics. 1992;89:
47–51.
442. Barton P, Garcia J, Kouatli A, Kitchen L, Zorka A, Lindsay C, Lawless
S, Giroir B. Hemodynamic effects of i.v. milrinone lactate in pediatric
Downloaded from
circ.ahajournals.org at NATIONAL TAIWAN UNIV on October 18, 2010